Saffron essential oil ameliorates CUMS-induced depression-like behavior in mice via the MAPK-CREB1-BDNF signaling pathway

Chen, Ziwei; Gu, Jinping; Lin, Susu; Xu, Zijin; Xu, Hongyu; Zhao, Jiajing; Feng, Peishi; Tao, Yi; Chen, Suhong; Wang, Ping

doi:10.1016/j.jep.2022.115719

Cited by 28 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings need to be confirmed in the future. The possible mechanisms by which saffron and its main constituents exert their antidepressant effects are currently thought to include the following: (1) crocin exhibits an antidepressant activity by inhibiting the uptake of dopamine and norepinephrine and increasing the levels of brain‐derived neurotrophic factor (BDNF), VGF neuropeptide, and cyclic AMP response element binding protein (CREB) (Chen et al, 2023; Dorri et al, 2015; Ghasemi et al, 2015); (2) saffron weakens hypothalamic–pituitary–adrenocortical hyperactivity by decreasing plasma levels of corticosterone (Ghadrdoost et al, 2011); and (3) saffron increases antioxidant capacity and attenuates inflammatory processes by suppressing nuclear factor kappa B (NF‐κB) signaling and the NOD‐like receptor family pyrin domain‐containing 3 (NLRP3) inflammasome pathway (Shafiee et al, 2018; Zhang et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms

Han,

Cao,

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Saffron (Crocus sativus), as an herbal medicine, has been extensively investigated for treating neurological and psychiatric disorders. This systematic review aimed to assess the overall effects of saffron on cognition, depression, anxiety, sleep disorders, attention‐deficit/hyperactivity disorder (ADHD), and obsessive–compulsive disorder (OCD). Relevant randomized controlled trials (RCTs) were identified by searching PubMed/Medline, Web of Science, and Clinical Trials databases up to June 2023 according to search terms and inclusion criteria. The participants were either healthy or suffering from some diseases, including neurological and psychiatric disorders, and consumed saffron or its extracts as an intervention. The risk of bias was assessed according to the Cochrane guidelines, and the PRISMA statement was followed. The meta‐analysis was performed using RevMan and STATA software. A random‐effects or fixed‐effects model was used to calculate the pooled effect sizes. Forty‐six RCTs were enrolled, and the duration of these trials ranged from 4 to 48 weeks with saffron or its extracts, both alone or in combination with conventional drugs. Saffron was more effective than placebo in improving cognition, depression with an overall effect size of −4.26 (95% CI: −5.76, −2.77), anxiety of −3.75 (95% CI: −5.83, −1.67), and sleep disorders of −1.91 (95% CI: −2.88, −0.93). Saffron was non‐inferior to conventional drugs for treating cognitive disorders, depression, anxiety, ADHD, and OCD, and it exhibited good tolerance with few side effects. Saffron may exert protective roles for neurological and psychiatric disorders and represents a relatively favorable and safe treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms

Han,

Cao,

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…The expression levels of FKBP5 [169] and STAT3 [1489] have been proved to be altered in COPD patients. Recent studies have shown that altered expression of FKBP5 [240], BRCA1 [1490], CREB1 [1491], MAX (MYC associated factor X) [1492], ESR1 [1493] and STAT3 [1494] might be associated with the progression of depression and anxiety. Studies have found that SHMT2 [625], TRIB3 [621], BRCA1 [1495] and STAT3 [1496] expression was associated with pulmonary hypertension.…”

Section: Discussionmentioning

confidence: 99%

Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis

Vastrad,

Vastrad

2024

Preprint

View full text Add to dashboard Cite

Identification of accurate biomarkers is still particularly urgent for improving the poor survival of chronic obstructive pulmonary disease (COPD) patients. In this investigation, we aimed to identity the potential biomarkers in COPD via bioinformatics and next generation sequencing (NGS) data analysis. In this investigation, the differentially expressed genes (DEGs) in COPD were identified using NGS dataset (GSE239897) from Gene Expression Omnibus (GEO) database. Subsequently, gene ontology (GO) and pathway enrichment analysis was conducted to evaluate the underlying molecular mechanisms involved in progression of COPD. Protein-protein interaction (PPI), modules, miRNA-hub gene regulatory network and TF-hub gene regulatory network analysis were performed to determine the hub genes, miRNAs and TFs. The receiver operating characteristic (ROC) analysis was performed to determine the diagnostic value of hub genes. A total of 956 overlapping DEGs (478 up regulated and 478 down regulated genes) were identified in the NGS dataset. DEGs were mainly associated with GO functional terms and pathways in cellular response to stimulus. response to stimulus, immune system and neutrophil degranulation. There were 10 hub genes (MYC, LMNA, VCAM1, MAPK6, DDX3X, SHMT2, PHGDH, S100A9, FKBP5 and RPS6KA2) identified by PPI, modules, miRNA-hub gene regulatory network and TF-hub gene regulatory network analysis. In conclusion, the DEGs, relative GO terms, pathways and hub genes identified in the present investigation might aid in understanding of the molecular mechanisms underlying COPD progression and provide potential molecular targets and biomarkers for COPD.

show abstract

“…Polyphenols may ameliorate depression by inhibiting the MAPK signaling pathway-dependent oxidative stress and inflammation in depression ( Behl et al, 2022 ). Recently, Chen et al (2023) showed the antidepressant potential of saffron essential oil in chronic unpredictable mild stress-induced depression in mice by regulating the MAPK-CREB1-BDNF signaling pathway. In another investigation, paroxetine, in combination with fluorouracil, alleviated depression in colorectal cancer mouse models by inhibiting the IL-22-dependent MAPK signaling pathway ( Zhang et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Integrating network pharmacology with molecular docking to rationalize the ethnomedicinal use of Alchornea laxiflora (Benth.) Pax & K. Hoffm. for efficient treatment of depression

Jain,

Tailang,

Chandrasekaran

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Alchornea laxiflora (Benth.) Pax & K. Hoffm. (A. laxiflora) has been indicated in traditional medicine to treat depression. However, scientific rationalization is still lacking. Hence, this study aimed to investigate the antidepressant potential of A. laxiflora using network pharmacology and molecular docking analysis.Materials and methods: The active compounds and potential targets of A. laxiflora and depression-related targets were retrieved from public databases, such as PubMed, PubChem, DisGeNET, GeneCards, OMIM, SwissTargetprediction, BindingDB, STRING, and DAVID. Essential bioactive compounds, potential targets, and signaling pathways were predicted using in silico analysis, including BA-TAR, PPI, BA-TAR-PATH network construction, and GO and KEGG pathway enrichment analysis. Later on, with molecular docking analysis, the interaction of essential bioactive compounds of A. laxiflora and predicted core targets of depression were verified.Results: The network pharmacology approach identified 15 active compounds, a total of 219 compound-related targets, and 14,574 depression-related targets with 200 intersecting targets between them. SRC, EGFR, PIK3R1, AKT1, and MAPK1 were the core targets, whereas 3-acetyloleanolic acid and 3-acetylursolic acid were the most active compounds of A. laxiflora with anti-depressant potential. GO functional enrichment analysis revealed 129 GO terms, including 82 biological processes, 14 cellular components, and 34 molecular function terms. KEGG pathway enrichment analysis yielded significantly enriched 108 signaling pathways. Out of them, PI3K-Akt and MAPK signaling pathways might have a key role in treating depression. Molecular docking analysis results exhibited that core targets of depression, such as SRC, EGFR, PIK3R1, AKT1, and MAPK1, bind stably with the analyzed bioactive compounds of A. laxiflora.Conclusion: The present study elucidates the bioactive compounds, potential targets, and pertinent mechanism of action of A. laxiflora in treating depression. A. laxiflora might exert an antidepressant effect by regulating PI3K-Akt and MAPK signaling pathways. However, further investigations are required to validate.

show abstract

Saffron essential oil ameliorates CUMS-induced depression-like behavior in mice via the MAPK-CREB1-BDNF signaling pathway

Cited by 28 publications

References 43 publications

New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms

New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms

Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis

Integrating network pharmacology with molecular docking to rationalize the ethnomedicinal use of Alchornea laxiflora (Benth.) Pax & K. Hoffm. for efficient treatment of depression

Contact Info

Product

Resources

About